Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence of Restless Leg Syndrome in Skin Biopsy Proven Small Fiber Neuropathy
Sleep
P1 - Poster Session 1 (12:00 PM-1:00 PM)
5-005

Associations between peripheral neuropathy and restless legs syndrome (RLS) are described but exact correlation remains inconsistent. Specifically, prevalence of RLS in histologically proven small fiber neuropathy (SFN) or correlation of RLS severity to SFN severity remains unknown. This study aims to address this void to improve quality of life (QOL) by identifying treatable comorbidity of RLS in SFN.

Dopaminergic dysfunction in RLS can lead to loss of supraspinal inhibition and enhanced excitability of propriospinal mechanisms. Additionally, abnormal sensory inputs in SFN worsen this inhibition secondary to altered dorsal horn physiology contributing to RLS.

A prospective study to assess prevalence of RLS in SFN is underway. We present preliminary results. 13 patients diagnosed with SFN showing reduced intradermal nerve fiber (IDNF) layer density were screened for RLS using standardized questionnaire based on the International RLS study group diagnostic criteria (IRLSRS). All patients who answered yes to three or four questions were considered screen-positive and further analysis regarding RLS severity was performed. We plan to study correlation of SFN severity based upon IDNF density to IRLSRS severity.

Out of 13 patients with SFN, 2 patients did not address all 4 questions. 9 patients endorsed 3 or 4 symptoms, and 2 patients endorsed 1 or 2 symptoms displaying RLS in 81.82% SFN. All 13 (100%) admitted unpleasant sensations combined with an urge to move legs and 10 (90.91%) noticed symptoms at rest or periods of inactivity. 6 (54.55%) admitted such sensations improved with movements and that such feelings were worse at night or evenings. The mean severity score was 26.33 and median 29 suggesting severe RLS per IRLSRS.

This study demonstrates that SFN is associated with RLS with significant impact on QOL.  Exploration of correlation between severity of SFN based on IDNF density to severity of RLS will enhance understanding of these comorbidities.

Authors/Disclosures
Urvi G. Desai, MD, FAAN (Dept of Neurology, CMC)
PRESENTER
Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx.
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with American Academy of Neurology that is relevant to AAN interests or activities.